Corporate promis join startup teams


Whether it’s the drones or life sciences industry, startups have common objectives when selecting their teams: to benefit from new know-how to bring their startup to the next level. Verity, Fotokite and Metriopharm have recently welcomed seasoned business personalities to their management board.


Verity, a global leader in indoor drone systems, has recently welcomed Fabrice Couadou a former executive member t Intel as the Head of Sales. Couadou will bring his more than 20 years of sales, business development, and marketing experience at Intel. He led business development projects for Intel’s EMEA drone business for the past several years. At Verity, Couadou will leverage this expertise in scaling the company’s live events business and bring it to the next level of commercial success. Another corporate prominent member in the drone sector is Craig Marcinkowski, the former Vice President of Strategy and Corporate Development for Gryphon Sensors LLC, an SRC Company, Inc. and Lockheed Martin. With nearly two decades of experience in the defense and aerospace industry, including P&L responsibilities, product development, software engineering, capture and program management, and domestic and international business development, Marcinkowski is a respected leader in the UAS space. In his new role as Vice President of Strategy and Business Development at Fotokite, the developer of tethered autonomous drones, Marcinkowski will begin by building a team of sales and service personnel to deliver world-class support to Fotokite’s U.S. Public Safety customer base. Fotokite was awarded the grand prize of $1M last year during the GENIUS NY accelerator. Since then the company has built up its first U.S office at The Tech Garden, which now has five full-time employees and currently looking to hire several more. Five successful exitsIn the life sciences sector, Metriopharm, developing a new class of drugs for the early treatment and long-term control of chronic inflammation with the aim of combating degenerative diseases of ageing, has appointed Sven Zimmermann to the position of Chief Financial Officer (CFO). Zimmermann holds a doctorate in molecular biology and initially worked as an analyst for the European biotech sector at UBS in Zurich and London. With his wealth of experience in corporate finance and capital raising, Zimmermann has managed five successful exits including the recent sale of the main asset of Novimmune SA to the Swedish Sobi AB for CHF 515 million. He was also co-responsible for the sale of PregLem SA to Gedeon Richter of Hungary for CHF 445 million in 2010 and the IPO of Auris Medical AG on NASDAQ of the US in 2014. Metriopharm will leverage not only his business know-how but also his scientific expertise, especially in the areas of immunology and inflammatory diseases. (RAN)Photo L-R: Fabrice Couadou (Verity), Craig Marcinkowski (Fotokite) and Sven Zimmermann (Metriopharm).